Linked Life Data

12008203

Source:http://linkedlifedata.com/resource/pubmed/id/12008203

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2002-5-14
pubmed:abstractText
We hypothesised that the combination of anti-angiogenic and anti-epidermal growth factor (EFG)-receptor (R) therapies would more effectively inhibit gastric cancer growth than single-agent therapy. TMK-1 gastric cancer cells were injected into the gastric wall of nude mice to generate tumours. After 4 days, mice were randomly assigned to the following groups: control, DC101 ([vascular endothelial growth factor (VEGF)-receptor (R)-2 antibody], C225 (EGF-R antibody), or a combination of DC101 and C225. The combination therapy significantly inhibited gastric tumour growth compared with the control group, whereas the decrease in tumour growth in mice treated with DC101 or C225 alone did not reach statistical significance. All mice administered DC101 demonstrated decreased tumour vascularity and increased endothelial cell apoptosis. C225 alone did not affect angiogenesis, but inhibited tumour cell proliferation. The combination therapy led to a further decrease in tumour cell proliferation. The combination of anti-VEGF-R and anti-EGF-R therapies was effective in inhibiting gastric cancer growth. These findings support the hypothesis that inhibiting multiple biological pathways that mediate tumour growth may be an effective therapeutic strategy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1133-40
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:12008203-Animals, pubmed-meshheading:12008203-Antibodies, Monoclonal, pubmed-meshheading:12008203-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12008203-Apoptosis, pubmed-meshheading:12008203-Cell Division, pubmed-meshheading:12008203-Immunohistochemistry, pubmed-meshheading:12008203-Mice, pubmed-meshheading:12008203-Mice, Nude, pubmed-meshheading:12008203-Neovascularization, Pathologic, pubmed-meshheading:12008203-Random Allocation, pubmed-meshheading:12008203-Receptor, Epidermal Growth Factor, pubmed-meshheading:12008203-Receptor Protein-Tyrosine Kinases, pubmed-meshheading:12008203-Receptors, Growth Factor, pubmed-meshheading:12008203-Receptors, Vascular Endothelial Growth Factor, pubmed-meshheading:12008203-Stomach Neoplasms, pubmed-meshheading:12008203-Tumor Cells, Cultured
pubmed:year
2002
pubmed:articleTitle
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model.
pubmed:affiliation
Deparment of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't